Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

NCT02100722 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).

Interventions

  • PROCEDURE CABG
  • PROCEDURE FFR guided PCI
  • DEVICE Resolute Integrity Stent
  • DEVICE Resolute Onyx Stent

Study Locations (20)

Other

  • Peninsula Health — Frankston
  • St. Vincent's Hospital Melbourne — Melbourne
  • Concord Hospital — Sydney
  • Royal North Shore — Sydney
  • University of Sydney — Sydney
  • Cardiovascular Center Aalst — Aalst
  • Le'Centre Hospitalier de l'Universite de Montreal — Montreal

California

  • Palo Alto VA — Palo Alto
  • Stanford University — Stanford

Kentucky

  • Lexinton VA — Lexington
  • University of Kentucky Medical Center — Lexington

Georgia

  • Atlanta VA Medical Center — Decatur

Illinois

  • Jesse Brown VA Medical Center — Chicago

Kansas

  • University of Kansas Medical Center — Lawrence

Massachusetts

  • Baystate Medical Center — Springfield

Minnesota

  • HealthEast St. Joseph's Hospital — Saint Paul

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2014-08-25
Est. Completion 2024-12-01
Phase NA

Sponsor

Stanford University

1,643 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02100722

The ClinicalTrials.gov registry entry for NCT02100722 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,643 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Coronary Disease appearing as the primary indexed condition, and to 4 interventions — of which CABG is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02100722 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Other, California, Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02100722 about?

NCT02100722 is a clinical study titled "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease". The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in sim...

What is the current status of trial NCT02100722?

This trial is currently completed. It is a NA study. The enrollment target is 1,500 participants. The study started on 2014-08-25. Estimated completion is 2024-12-01.

What conditions does trial NCT02100722 study?

This clinical trial studies the following conditions: Coronary Disease, Coronary Stenosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02100722?

The interventions under investigation include: CABG (PROCEDURE), FFR guided PCI (PROCEDURE), Resolute Integrity Stent (DEVICE), Resolute Onyx Stent (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02100722?

This trial is sponsored by Stanford University, which has 1,643 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02100722 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial